2024’s Breakthrough in Monoclonal Antibody Development: Insights from WuXi-BioNTech’s Landmark Deal The rapid evolution of monoclonal antibody development in 2024 marks a significant era in
COLUMBIA, Maryland, September 7, 2020: A&G Pharmaceutical Inc., and its Custom Antibody Division Precision Antibody’s Progranulin ELISA kit used to investigate the correlation between progranulin
COLUMBIA, Maryland, September 7, 2020: A&G Pharmaceutical Inc., and its Custom Antibody Division Precision Antibody’s Progranulin ELISA kit used to investigate the correlation between progranulin serum
In the wake of a groundbreaking article published in the Washington Post on November 12th, we were captivated by the strides made by Cessation Therapeutics
COLUMBIA, Maryland, August 31, 2020: A&G Pharmaceutical, Inc (A&G), with its Custom Antibody Division Precision Antibody has developed mouse monoclonal antibodies (mAbs) against COVID-19 antigens;
Precision Antibody contributes to the development of novel antibody reagents for the RAS signaling network The National Cancer Institute (NCI)’s RAS initiative has been working
Columbia, Maryland – Dr. Ginette Serrero, CEO of A&G Pharmaceutical Inc., DBA Precision Antibody, will present two posters at the American Association of Cancer Research’s
Internalization assays play a vital role in antibody research and development by allowing scientists to investigate the uptake and intracellular trafficking of antibodies. These assays
COLUMBIA, Maryland, February 10, 2021: Precision Antibody and A&G Pharmaceutical are pleased to announce the publication, in PLOS One, of the results of their collaborative study
In the realm of therapeutic antibodies, precision is paramount. The development of anti-idiotypic antibodies (anti-IDs) has emerged as a revolutionary force in pharmacokinetic analysis and
We pride ourselves on our customer service!
